TaiFu Biopharmaceutical 2025 Q4 Financial Report
Key facts
- TaiFu Biopharmaceutical 2025 Q4 Financial Report
- TaiFu Biopharmaceutical (Company Code: 6541) reported a basic EPS of -6.13 NTD for Q4 2025. The company's operating revenue was 401 million NTD, with a net loss after tax of 1.5 billion NTD.
- Source: PR Times
- Date: December 1, 2025
Direct answer
TaiFu Biopharmaceutical (Company Code: 6541) reported a basic EPS of -6.13 NTD for Q4 2025. The company's operating revenue was 401 million NTD, with a net loss after tax of 1.5 billion NTD.
- Citation
- TaiFu Biopharmaceutical 2025 Q4 Financial Report (December 1, 2025), PR Times
- Source
- PR Times
- Date
- December 1, 2025
TaiFu Biopharmaceutical (Company Code: 6541) reported a basic EPS of -6.13 NTD for Q4 2025. The company's operating revenue was 401 million NTD, with a net loss after tax of 1.5 billion NTD.
📋 Article Processing Timeline
- 📰 Published: December 1, 2025 at 09:00
- 🔍 Collected: April 7, 2026 at 08:00 (3047h 0m after Published)
- 🤖 AI Analyzed: April 8, 2026 at 00:21 (16h 20m after Collected)
Company Code: 6541 Company Name: TaiFu Biopharmaceutical Co., Ltd. Industry: Biotechnology and Medical Care Year/Quarter: 2025 Q4 Basic Earnings Per Share: -6.13 NTD Operating Revenue: 401 million NTD Net Income After Tax: -1.5 billion NTD
FAQ
What are the key facts in this article?
TaiFu Biopharmaceutical (Company Code: 6541) reported a basic EPS of -6.13 NTD for Q4 2025. The company's operating revenue was 401 million NTD, with a net loss after tax of 1.5 billion NTD.
What is the direct answer?
TaiFu Biopharmaceutical (Company Code: 6541) reported a basic EPS of -6.13 NTD for Q4 2025. The company's operating revenue was 401 million NTD, with a net loss after tax of 1.5 billion NTD.
What is the source and date?
PR Times: https://openapi.twse.com.tw/financial/twse-fin-6541-2025Q4 | December 1, 2025